EPIGENETIC REGULATION OF F508DEL-CFTR IN CYSTIC FIBROSIS LUNG DISEASE

被引：0
|
作者：
Kumar, P. [1 ]
Frizzell, R. A. [2 ]
Pollard, H. [1 ]
Biswas, R. [1 ]
机构：
[1] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA
[2] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA
来源：
PEDIATRIC PULMONOLOGY | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
34
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [41] Correctors modify the bicarbonate permeability of F508del-CFTR
    Fiore, Michele
    Picco, Cristiana
    Moran, Oscar
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [42] Reply to 'F508del-CFTR is not corrected by thymosin α1'
    Romani, Luigina
    Stincardini, Claudia
    Giovagnoli, Stefano
    Paci, Maurizio
    Villella, Valeria R.
    Sforna, Luigi
    Renga, Giorgia
    Bellet, Marina M.
    Costantini, Claudio
    Puccetti, Paolo
    Kroemer, Guido
    Maiuri, Luigi
    Pessia, Mauro
    Goldstein, Allan
    Garaci, Enrico
    NATURE MEDICINE, 2018, 24 (07) : 891 - 893
  • [43] IBUPROFEN ACTS AS A TRAFFICKING CORRECTOR OF F508DEL-CFTR
    Carlile, G. W.
    Robert, R.
    Goepp, J.
    Liao, J.
    Rotin, D.
    Kus, B.
    Hanrahan, J. W.
    Thomas, D. Y.
    PEDIATRIC PULMONOLOGY, 2011, : 219 - 219
  • [44] Correctors modify the bicarbonate permeability of F508del-CFTR
    Michele Fiore
    Cristiana Picco
    Oscar Moran
    Scientific Reports, 10
  • [45] DISCOVERY AND CHARACTERIZATION OF POTENT F508DEL-CFTR CORRECTORS
    Bandiera, T.
    Sorana, F.
    Berti, F.
    Rodriguez-Gimeno, A.
    Di Fruscia, P.
    Brindani, N.
    Bertozzi, Mandrup S.
    Ottonello, G.
    Armirotti, A.
    Span, R.
    Bertorelli, R.
    Penna, I
    Margaroli, N.
    Russo, D.
    Caci, E.
    Ferrera, L.
    Tomati, V
    Pesce, E.
    Scudieri, P.
    Bertozzi, F.
    Pedemonte, N.
    Galietta, L. J.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S217 - S217
  • [46] Reply to ‘F508del-CFTR is not corrected by thymosin α1’
    Luigina Romani
    Claudia Stincardini
    Stefano Giovagnoli
    Maurizio Paci
    Valeria R. Villella
    Luigi Sforna
    Giorgia Renga
    Marina M. Bellet
    Claudio Costantini
    Paolo Puccetti
    Guido Kroemer
    Luigi Maiuri
    Mauro Pessia
    Allan Goldstein
    Enrico Garaci
    Nature Medicine, 2018, 24 : 891 - 893
  • [47] PULMONARY EXACERBATIONS, LUNG DYSFUNCTION, AND EQ-5D MEASURES IN ADOLESCENTS AND ADULTS WITH CYSTIC FIBROSIS AND HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION
    Solem, C. T.
    Vera-Llonch, M.
    Tai, M.
    O'Callaghan, L.
    VALUE IN HEALTH, 2016, 19 (03) : A116 - A117
  • [48] CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR
    Wang, Yiting
    Liu, Jia
    Loizidou, Avgi
    Bugeja, Luc A.
    Warner, Ross
    Hawley, Bethan R.
    Cai, Zhiwei
    Toye, Ashley M.
    Sheppard, David N.
    Li, Hongyu
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (19) : 4490 - 4503
  • [49] Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia
    Sondo, Elvira
    Falchi, Federico
    Caci, Emanuela
    Ferrera, Loretta
    Giacomini, Elisa
    Pesce, Emanuela
    Tomati, Valeria
    Bertozzi, Sine Mandrup
    Goldoni, Luca
    Armirotti, Andrea
    Ravazzolo, Roberto
    Cavalli, Andrea
    Pedemonte, Nicoletta
    CELL CHEMICAL BIOLOGY, 2018, 25 (07): : 891 - +
  • [50] An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)
    Flume, P.
    Biner, Fischer R.
    Downey, D. G.
    Brown, C.
    Jain, M.
    Fischer, R.
    de Boeck, C.
    Campbell, D.
    Wang, X.
    Ahluwalia, N.
    Owen, C. A.
    Wainwright, C.
    PNEUMOLOGIE, 2020, 74 : S87 - S87
12345